A share price of Monte Rosa Therapeutics Inc [GLUE] is currently trading at $5.99, up 2.92%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The GLUE shares have gain 8.32% over the last week, with a monthly amount drifted -17.04%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Monte Rosa Therapeutics Inc [NASDAQ: GLUE] stock has seen the most recent analyst activity on December 19, 2024, when Wells Fargo downgraded its rating to a Equal Weight and also revised its price target to $11 from $14. Previously, Wedbush started tracking the stock with Outperform rating on February 15, 2024, and set its price target to $11. On January 03, 2023, upgrade upgraded it’s rating to Overweight but maintained its price target of $18 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $22 on October 13, 2022. Jefferies initiated its recommendation with a Buy and recommended $20 as its price target on August 15, 2022. Credit Suisse started tracking with a Neutral rating for this stock on April 28, 2022, and assigned it a price target of $19. In a note dated February 10, 2022, Wells Fargo initiated an Equal Weight rating and provided a target price of $19 on this stock.
Monte Rosa Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $3.21 and $12.40. Monte Rosa Therapeutics Inc [NASDAQ: GLUE] shares were valued at $5.99 at the most recent close of the market.
Analyzing the GLUE fundamentals
Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -5.44%, Pretax Profit Margin comes in at -5.02%, and Net Profit Margin reading is -5.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.63 and Total Capital is -0.47. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.79 points at the first support level, and at 5.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.09, and for the 2nd resistance point, it is at 6.20.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Monte Rosa Therapeutics Inc [NASDAQ:GLUE] is 6.03. In addition, the Quick Ratio stands at 6.03 and the Cash Ratio stands at 3.02. Considering the valuation of this stock, the price to sales ratio is 24.58, the price to book ratio is 1.79.
Transactions by insiders
Recent insider trading involved Versant Venture Capital VI, L., 10% Owner, that happened on Oct 28 ’24 when 89990.0 shares were sold. 10% Owner, Versant Venture Capital VI, L. completed a deal on Oct 29 ’24 to sell 67905.0 shares. Meanwhile, Officer Wallace Owen B. bought 20000.0 shares on Oct 28 ’24.
